Validated GC–MS analysis for the determination of residual fentanyl in applied Durogesic® reservoir and Durogesic® D-Trans® matrix transdermal fentanyl patches - ScienceDirect

Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic (R) reservoir and Durogesic (R) D-Trans (R) matrix transdermal fentanyl patches

Predicting transdermal fentanyl delivery using physics-based simulations for tailored therapy

US9642850B2 - Method of providing sustained analgesia with buprenorphine - Google Patents

Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic (R) reservoir and Durogesic (R) D-Trans (R) matrix transdermal fentanyl patches

Transdermal fentanyl matrix patches Matrifen® and Durogesic® DTrans® are bioequivalent - ScienceDirect

Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic (R) reservoir and Durogesic (R) D-Trans (R) matrix transdermal fentanyl patches

PDF) A Fatal Case of Poisoning with Fentanyl Transdermal Patches in Japan

PDF) A Fatal Case of Poisoning with Fentanyl Transdermal Patches in Japan

Validated GC-MS analysis for the determination of residual fentanyl in applied Durogesic (R) reservoir and Durogesic (R) D-Trans (R) matrix transdermal fentanyl patches

Transdermal Matrix Fentanyl Membrane Patch (Matrifen®)

Fentanyl transdermal patch, 2.5 mg.